ALT Q1 2021 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$838,000-62.1% YoY

Gross Profit

-$10M-1212.4% margin

Operating Income

-$15M-1773.4% margin

Net Income

-$15M-1773.7% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

-63.8%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$24M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$264M

Total Liabilities

$18M

Stockholders' Equity

$246M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$838,000	$2M	-62.1%
Gross Profit	-$10M	-$3M	-215.1%
Operating Income	-$15M	-$7M	-103.4%
Net Income	-$15M	-$4M	-282.5%

Revenue Segments

Grant

$200,000100%